PARP1 and Schinzel-Giedion syndrome: Thus, if excessive PARP-1 activity, PAR levels, NAD+ depletion, and/or parthanatos are responsible for neurological defects seen in SGS patients, either currently available catalytic PARP-1 inhibitors or NAD+ repletion, may represent valuable therapeutic options76.